Plain-English translation of NCT04427566 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing ultra low-dose whole lung radiation therapy as a potential treatment for people with severe COVID-19 who are so sick they need a breathing machine (mechanical ventilator) in the ICU. Researchers want to see if this radiation treatment might help reduce inflammation in the lungs and improve survival. The study will enroll up to 24 patients and track their outcomes over 30 days.
In the early stages of the COVID-19 pandemic, doctors were looking for new ways to help critically ill patients whose lungs were severely damaged. This trial was designed to explore whether low-dose radiation — which can reduce harmful inflammation — might give these patients a better chance of survival when used alongside standard ICU care.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive a single low-dose radiation treatment to your whole lungs while in the ICU. After 3–10 days, your doctors may give you a second optional dose if the first treatment hasn't improved your condition. Your medical team will closely monitor you throughout your ICU stay and track your recovery, oxygen levels, and whether you can be taken off the breathing machine. The study will follow your progress for at least 30 days after you start the radiation treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States